NEW YORK, June 18, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Health Management Associates Inc. (NYSE: HMA), IDEXX Laboratories, Inc. (NASDAQ: IDXX), ISIS Pharmaceuticals Inc. (NASDAQ: ISIS), and Trius Therapeutics Inc. (NASDAQ: TSRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Gilead Sciences, Inc. Research Report
On June 7, 2013, Gilead Sciences Inc. (Gilead) announced that the US Food and Drug Administration (FDA) has granted priority review to the New Drug Application (NDA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C (HCV) infection. Priority review status is granted to drug candidates that may offer major advances in treatment over existing options. According to Gilead, the data submitted in the NDA support the use of sofosbuvir and ribavirin (RBV) as an all-oral therapy for patients with genotype 2 and 3 HCV infection, and of sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) for treatment-naïve patients with genotype 1,4, 5, and 6 HCV infection. The Company filed the NDA for sofosbuvir on April 8, 2013, and FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of December 8, 2013. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/9696_GILD]
Health Management Associates Inc. Research Report
On June 11, 2013, Health Management Associates Inc. (Health Management) announced that it has executed a letter of intent under which it would enter into a long-term lease with Munroe Regional Medical Center (Munroe Regional) and bring it into Health Management's clinical affiliation with the University of Florida Health Shands Hospital. The letter of intent is the first step of a due diligence process between Munroe Regional, Health Management, and UF Health Shands Hospital toward a definitive agreement. Alan Levine, Senior Vice President and Florida Group President for Health Management, said, "By combining the talents of Munroe Regional, the resources of Health Management and the academic strength of UF Health Shands Hospital, the partnership will provide the region the best opportunity to strengthen and improve the health of the community for years to come." The three parties involved expect to execute the definitive agreement by Q4 2013, and complete the new partnership before the end of 2013. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/96e5_HMA]
IDEXX Laboratories, Inc. Research Report
On June 13, 2013, IDEXX Laboratories, Inc. (IDEXX) announced that it is partnering with laboratories worldwide to offer confirmatory pregnancy testing using milk samples with the new IDEXX Milk Pregnancy Test. With this test, dairy farmers can get early, accurate identification of open cows by simply requesting the IDEXX Milk Pregnancy Test for samples they already submitted for milk-quality testing, or by sending samples directly to participating laboratories. According to the Company, the IDEXX Milk Pregnancy Test uses trusted ELISA technology to detect pregnancy-associated glycoproteins (PAGs) and determine pregnancy. It can provide accurate information as early as 35 days post breeding and also provides accuracy similar to that of palpation and ultrasound, while also minimizing animal handling. The Full Research Report on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/b565_IDXX]
ISIS Pharmaceuticals Inc. Research Report
On June 10, 2013, Isis Pharmaceuticals Inc. (Isis) and Xenon Pharmaceuticals Inc. (Xenon) announced that Xenon has exercised its option to an exclusive worldwide license to XEN701, an antisense drug that was discovered as a result of collaboration between the two companies. Xenon plans to initially develop XEN701 for patients with chronic kidney disease who are intolerant of or who are poor responders to erythropoietin (Epo) therapy. B. Lynne Parshall, Chief Operating Officer at Isis, said, "By working with partners like Xenon, who are highly innovative and dedicated to a therapeutic area, we are able to expand the breadth of our antisense drug pipeline while staying focused on our internal drug discovery and development activities." Subsequent to this step, Isis earns a $2 million payment from Xenon for the license of XEN701. The Full Research Report on ISIS Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/f5f5_ISIS]
Trius Therapeutics Inc. Research Report
On June 12, 2013, Trius Therapeutics Inc. (Trius Therapeutics) announced the publication of the results from multiple clinical and animal studies showing that the Company's experimental antibiotic, tedizolid phosphate (TR-701), does not interact with monamine oxidase (MAO). The results were published in the July 2013 (Volume 57 Number 7) print issue of Antimicrobial Agents and Chemotherapy. According to Trius Therapeutics, the findings suggest that, if approved, tedizolid could potentially be taken with commonly prescribed medicines such as many antidepressants, whose use is limited with agents that inhibit MAO. The Company will include these results in its new drug application (NDA) for tedizolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI), which it plans to file in the second half of 2013. The Full Research Report on Trius Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1eb9_TSRX]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
|SOURCE Wall Street Reports|
Copyright©2012 PR Newswire.
All rights reserved